Comparing Check-Cap (NASDAQ:MBAI) & Profusa (NASDAQ:PFSA)

Check-Cap (NASDAQ:MBAI) and Profusa (NASDAQ:PFSA) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares Check-Cap and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Profusa	N/A	N/A	-1,348.07%

Valuation & Earnings

This table compares Check-Cap and Profusa”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14 million	($2.77)	-0.54
Profusa	$100,000.00	13.56	-$35.82 million	($169.72)	0.00

Check-Cap has higher earnings, but lower revenue than Profusa. Check-Cap is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 0.8% of Profusa shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Profusa has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Check-Cap and Profusa, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1	0	0	0	1.00
Profusa	1	0	0	0	1.00

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.